COVID-19 and the High Cost of Dying

If the FDA approves remdesivir for treating Covid-19, which is by no means guaranteed, Gilead will be able to charge what it likes until 2037. Until then, you can forget about a cheap generic version of the drug.

Related:

Joe Grogan, Trump’s Top Domestic Policy Aide, Leaving White House Next Month

Grogan — who worked as a lobbyist for drugmaker Gilead prior to his time at the White House — has played a significant role in crafting major health policies, including drug pricing, for the Trump administration.